Re: NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the
http://www.novartisoncology.com/rese...n/pipeline.jsp
BEZ235 is in Phase I/II clinical trials in the pipeline at NovartisOncology.
There are 50 open trials for breast cancer with Novartis products:
http://clinicaltrials.gov/ct2/result...=Open&no_unk=Y
|